Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.6
Journals
Molecules
Special Issues
Anti-inflammatory Drugs as a Treatment for Psychiatric Disorders
molecules-logo
Submit to Molecules Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Anti-inflammatory Drugs as a Treatment for Psychiatric Disorders

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (15 October 2020) | Viewed by 10006

Special Issue Editor

Dr. Abed N. Azab

E-Mail Website
Guest Editor
Department of Nursing, School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
Interests: anti-inflammatory drugs; cytokines; glia cells; neuro-inflammation; pharmacology; prostaglandins; psychopharmacology; psychiatric disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, data have accumulated suggesting that inflammation may contribute to the pathophysiology of psychiatric disorders such as depression, bipolar disorder, and schizophrenia. Supporting findings include the following: (i) patients with psychiatric disorders were found to have increased levels of pro-inflammatory mediators in the plasma and in postmortem brain samples; (ii) psychotropic medications exhibited potent anti-inflammatory effects both in animal and human studies; and (iii) classic anti-inflammatory drugs such as corticosteroids and nonsteroidal anti-inflammatory drugs exerted beneficial effects in patients with psychiatric disorders.

This Special Issue will address the role of anti-inflammatory drugs as a treatment for psychiatric disorders. Original articles and review papers that cover anti-inflammatory and anti-infectious drugs as potential treatment for psychiatric disorders are welcomed.

Dr. Abed N. Azab
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Anti-inflammatory drugs
  • Bipolar affective disorder
  • Corticosteroids
  • COX inhibitors
  • C-reactive protein
  • Cytokines
  • Depression
  • Efficacy
  • Minocycline
  • Immune disturbances
  • Inflammation
  • Mood disorders
  • Prostaglandins
  • Psychiatric Illnesses
  • Schizophrenia
  • Side effects

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 1553 KiB  
Review
Anti-TNF-α Compounds as a Treatment for Depression
by Sarit Uzzan and Abed N. Azab
Molecules 2021, 26(8), 2368; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26082368 - 19 Apr 2021
Cited by 49 | Viewed by 5508
Abstract
Millions of people around the world suffer from psychiatric illnesses, causing unbearable burden and immense distress to patients and their families. Accumulating evidence suggests that inflammation may contribute to the pathophysiology of psychiatric disorders such as major depression and bipolar disorder. Copious studies [...] Read more.
Millions of people around the world suffer from psychiatric illnesses, causing unbearable burden and immense distress to patients and their families. Accumulating evidence suggests that inflammation may contribute to the pathophysiology of psychiatric disorders such as major depression and bipolar disorder. Copious studies have consistently shown that patients with mood disorders have increased levels of plasma tumor necrosis factor (TNF)-α. Given these findings, selective anti-TNF-α compounds were tested as a potential therapeutic strategy for mood disorders. This mini-review summarizes the results of studies that examined the mood-modulating effects of anti-TNF-α drugs. Full article
(This article belongs to the Special Issue Anti-inflammatory Drugs as a Treatment for Psychiatric Disorders)
►▼ Show Figures

Figure 1

26 pages, 3512 KiB  
Review
Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders
by Maria Grazia Perrone, Antonella Centonze, Morena Miciaccia, Savina Ferorelli and Antonio Scilimati
Molecules 2020, 25(22), 5388; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules25225388 - 18 Nov 2020
Cited by 16 | Viewed by 4087
Abstract
According to the World Health Organization, the major psychiatric and neurodevelopmental disorders include major depression, bipolar disorder, schizophrenia, and autism spectrum disorder. The potential role of inflammation in the onset and progression of these disorders is increasingly being studied. The use of non-steroidal [...] Read more.
According to the World Health Organization, the major psychiatric and neurodevelopmental disorders include major depression, bipolar disorder, schizophrenia, and autism spectrum disorder. The potential role of inflammation in the onset and progression of these disorders is increasingly being studied. The use of non-steroidal anti-inflammatory drugs (NSAIDs), well-known cyclooxygenase (COX) inhibitors, combined with first-choice specific drugs have been long investigated. The adjunctive administration of COX inhibitors to classic clinical treatments seems to improve the prognosis of people who suffer from psychiatric disorders. In this review, a broad overview of the use of COX inhibitors in the treatment of inflammation-based psychiatric disorders is provided. For this purpose, a critical analysis of the use of COX inhibitors in the last ten years of clinical trials of the major psychiatric disorders was carried out. Full article
(This article belongs to the Special Issue Anti-inflammatory Drugs as a Treatment for Psychiatric Disorders)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop